Adaptin Bio (APTN) Return on Capital Employed (2024 - 2026)

Adaptin Bio has disclosed Return on Capital Employed across 3 years of filings, most recently posting 75.8% for Q1 2026.

• Quarterly Return on Capital Employed rose 35127.0% year-over-year to 75.8% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 75.8% (up 35127.0% YoY) and the FY2025 annual result came in at 64.62%, up 4908.0% from the prior year.
• Return on Capital Employed retreated to 75.8% in Q1 2026, from 82.89% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 890.69% in Q3 2024 and bottomed at 275.47% in Q1 2025.
• The 3-year median for Return on Capital Employed is 79.34% (2025), against an average of 206.52%.
• Year-over-year, Return on Capital Employed plunged 73955 bps in 2025 and jumped 35127 bps in 2026.
• Adaptin Bio's Return on Capital Employed stood at 15.54% in 2024, then surged by 433 bps to 82.89% in 2025, then retreated by 9 bps to 75.8% in 2026.
• According to Business Quant data, Return on Capital Employed over the past three periods registered 75.8%, 82.89%, and 489.5% for Q1 2026, Q4 2025, and Q3 2025 respectively.